Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.
about
Emerging Role of Genomic Rearrangements in Breast Cancer: Applying Knowledge from Other CancersThe fate of chemoresistance in triple negative breast cancer (TNBC)Revealing the Complexity of Breast Cancer by Next Generation SequencingTargeted Therapies in Triple-Negative Breast CancerIntratumoral heterogeneity: Clonal cooperation in epithelial-to-mesenchymal transition and metastasisGenomic profiling of breast cancersProgress in the clinical detection of heterogeneity in breast cancerRegulation of PI3K effector signalling in cancer by the phosphoinositide phosphatasesERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.Intratumoral Morphological Heterogeneity of Breast Cancer As an Indicator of the Metastatic Potential and Tumor Chemosensitivity.Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.MYC Deregulation in Primary Human Cancers.Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants.The AURORA initiative for metastatic breast cancer.Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences.Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance?Network-based stratification analysis of 13 major cancer types using mutations in panels of cancer genes.Nuclear basic fibroblast growth factor regulates triple-negative breast cancer chemo-resistanceMutational Profiling Can Establish Clonal or Independent Origin in Synchronous Bilateral Breast and Other Tumors.Subclonal diversification of primary breast cancer revealed by multiregion sequencing.Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications.Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration.Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.CCR 20th Anniversary Commentary: Simpson's Paradox and Neoadjuvant TrialsMitotic MELK-eIF4B signaling controls protein synthesis and tumor cell survivalNext generation sequencing of triple negative breast cancer to find predictors for chemotherapy response.MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity.Targeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advancesClinical implications of molecular heterogeneity in triple negative breast cancer.Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.The current use and attitudes towards tumor genome sequencing in breast cancer.RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint InhibitorsMyeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.MUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors.A Combination of Targeted Therapy with Chemotherapy Backbone Induces Response in a Treatment-Resistant Triple-Negative MCL1-Amplified Metastatic Breast Cancer Patient.miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer.MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib.The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis.Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers.
P2860
Q26766271-653E30DB-6CD1-4C47-A386-CD3B9D6AC7C0Q26775232-AD217F97-F061-4654-A197-C6E3594F4A75Q26777395-ACC3A743-9277-4DE3-B4D2-0057E67E625EQ26777736-28A7B73B-5804-44F1-8F60-12EFB319748BQ26991480-78832884-AD25-4F76-9409-07D4E4055D94Q27013013-AE028F18-4363-4F55-9A38-CFDD4A37833CQ28079224-7E76AE9D-6932-4E36-9B0D-309237F7900AQ29248612-44761978-EAC6-4E3B-9E31-1B6D52CA34A9Q33601653-D44007B6-8CBD-4C75-B475-EAC536C0DC27Q33607816-00864FC8-A51C-408D-9B25-389D61D11302Q33769821-408BF8AF-C193-4CCF-A986-C8B51D3DB388Q33836755-3A718DA3-DA11-4202-B0AA-D512CC294EEEQ33915057-518EF1E4-C5BC-449D-802B-9D0EDC27C726Q34499602-BA214987-768D-46E0-B2BE-F82487A24ED4Q34654793-E7325121-D4EF-4821-9883-076B28E9AE5BQ35551802-1A5F66DA-BA6C-4C0D-8F36-71C93FA03158Q35671019-2FFEA87D-F5AB-4C7C-9FB9-5C3BA16B3117Q35816889-1E15BB35-E866-4911-8E0F-27C595A5B647Q35836960-AB246AE2-2739-48A6-B3DF-D47955316338Q35847434-94C5DA9A-1450-4B0C-870A-8E4A87AADECCQ35895214-B31325BA-6863-4535-8836-AF4D57BAB969Q35938054-26EBE5C1-9414-4F56-BCAD-145E199D5701Q35952998-74A62CD2-5904-4200-97C9-8A07E7D016D9Q36064946-586C5356-7B24-4BED-9C0F-8078087A0F4CQ36069527-3320A67E-A104-4032-9618-7F145F754EADQ36104705-05FB5FBB-FA72-429A-A70A-3F88D56A7925Q36119077-51CD26C5-38F2-4335-8FF0-18F73E9B1CF2Q36157026-CF268FE5-8094-45D5-8B52-F3E68C63792BQ36157045-00C9A521-6508-4099-B0A4-6EAE393EDF9FQ36271396-79A81D99-76A1-4D17-94F4-EBA4FF04D785Q36413493-0A54BABD-F75A-4AC6-A467-CFF38A3020BBQ36638214-4F1FF9F1-158F-4C29-BE0D-E68465CF55AFQ36693087-BE0058F3-DDF1-4862-9CE6-75AEECEA7DAFQ36751571-470C675A-422F-4D26-AD8A-5EF457899644Q36928457-DA8C8903-4351-47EA-A680-C9757417EF85Q36985683-F81FBF5B-8A3D-49E2-B1C1-89F3B4700B96Q37412557-C1159E50-43D9-44D0-BFAB-D123B8100DB5Q37487789-88F72887-5C45-475B-89CF-C94C69A3232AQ37510518-B4B62D34-825E-49A3-B9CA-F39DA5120C71Q37536016-2BA88DA8-895D-466C-946D-0A25815B95BB
P2860
Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Molecular profiling of the res ...... ctionable therapeutic targets.
@en
Molecular profiling of the res ...... ctionable therapeutic targets.
@nl
type
label
Molecular profiling of the res ...... ctionable therapeutic targets.
@en
Molecular profiling of the res ...... ctionable therapeutic targets.
@nl
prefLabel
Molecular profiling of the res ...... ctionable therapeutic targets.
@en
Molecular profiling of the res ...... ctionable therapeutic targets.
@nl
P2093
P2860
P50
P1433
P1476
Molecular profiling of the res ...... ctionable therapeutic targets.
@en
P2093
Andrei Goga
Carlos L Arteaga
Christian D Young
Dai Horiuchi
Franco D Doimi
Gary A Palmer
Jeffrey S Ross
Jennifer A Pietenpol
Jennifer M Giltnane
Joshua A Bauer
P2860
P304
P356
10.1158/2159-8290.CD-13-0286
P577
2013-12-19T00:00:00Z